MyFinsight
Home
Blog
About
Short-term investments
$197,601K
(14.88%↑ Y/Y)
Cash and cash
equivalents
$154,972K
(76.04%↑ Y/Y)
Trade receivables
$110,757K
(21.47%↑ Y/Y)
Prepaid expenses and
other current assets
$14,818K
(18.16%↑ Y/Y)
Inventory, net
$6,056K
(20.06%↑ Y/Y)
Restricted cash
$479K
(-2.64%↓ Y/Y)
Total current assets
$484,683K
(21.64%↑ Y/Y)
Long-term inventory, net
$31,945K
(43.86%↑ Y/Y)
Other assets
$19,557K
(444.46%↑ Y/Y)
Right of use assets,
net
$12,608K
(9.20%↑ Y/Y)
Property and equipment,
net
$9,058K
(7.11%↑ Y/Y)
Total assets
$557,851K
(22.02%↑ Y/Y)
Accumulated deficit
-$2,149,596K
(-21.80%↓ Y/Y)
Accumulated other
comprehensive (loss) income
-$528K
(-132.08%↓ Y/Y)
Total liabilities and
stockholders deficit
$557,851K
(22.02%↑ Y/Y)
Total stockholders
deficit
-$454,289K
(-7.76%↓ Y/Y)
Additional paid-in capital
$1,693,282K
(26.40%↑ Y/Y)
Common stock, 0.01 par
value shares...
$2,553K
(21.63%↑ Y/Y)
Total liabilities
$1,012,140K
(15.18%↑ Y/Y)
Secured term loan
$395,400K
(62.85%↑ Y/Y)
Royalty financing
obligations
$382,981K
(-14.48%↓ Y/Y)
Total current
liabilities
$208,846K
(17.89%↑ Y/Y)
Deferred revenue
$13,461K
Operating lease
liabilities
$10,603K
(24.90%↑ Y/Y)
Finance lease
liabilities
$849K
(-58.44%↓ Y/Y)
Accrued expenses
$121,895K
(13.80%↑ Y/Y)
Royalty financing
obligations
$43,808K
(22.57%↑ Y/Y)
Share-based liability
$16,360K
Deferred revenue
$12,320K
Accounts payable
$11,459K
(33.41%↑ Y/Y)
Operating lease
liabilities
$1,912K
(387.76%↑ Y/Y)
Finance lease
liabilities
$1,092K
(-32.43%↓ Y/Y)
Back
Back
Balance Sheet
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)
source: myfinsight.com